The bispecific antibody cadonilimab (AK104), which targets PD-1 and CTLA-4 simultaneously while lacking an Fc region to prevent inflammatory cytokine secretion, has demonstrated favorable safety profiles and encouraging antitumor activity in cervical cancer, NSCLC, and hepatocellular carcinoma [129]. Here, CTLA4 is linked to non-small cell lung carcinoma.